Vital Therapies Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

SAN DIEGO, March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

“Since the FDA’s response to our Type C submission on our proposed VTL-308 trial in November, we have started to open clinical trial sites and are preparing for the trial,” said Terry Winters, Ph.D., Chief Executive Officer and Co-Chairman of Vital Therapies. “We look forward to enrolling the first subject in VTL-308 during the first half of this year.”

Back to news